Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Bevacizumab vs IFN + Bevacizumab in First-line Metastatic RCC
NCT00719264Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of everolimus in clear cell renal cell carcinoma (ccRCC), sponsored by Novartis. Started Nov 2008; status: completed.
02
Drugs
everolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00719264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719264.